Full Press Release Details
regeneron announces positive phase 3 trial in adults with ultra rare genetic disorder fibrodysplasia ossificans progressiva fop demonstrating that garetosmab prevents greater than.
REGN
regeneron announces positive phase 3 trial in adults with ultra rare genetic disorder fibrodysplasia ossificans progressiva fop demonstrating that garetosmab prevents greater than
Key Takeaway: regeneron announces positive phase 3 trial in adults with ultra rare genetic disorder fibrodysplasia ossificans progressiva fop demonstrating that garetosmab prevents greater than